Tag Archives: CMP-001

Turning “cold tumors hot” – rationale, major setback, and promise

One of the most active fields of clinical investigation in immuno-oncology today is augmenting responses to checkpoint [CTLA4 or PD-(L)1] inhibition therapy by re-sensitizing tumors that were initially unresponsive or had stopped responding to treatment. Continue reading